{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:46:12Z","timestamp":1760298372281},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mod Rheumatol"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s10165-011-0472-1","type":"journal-article","created":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T23:26:03Z","timestamp":1306970763000},"page":"94-99","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases"],"prefix":"10.1093","volume":"22","author":[{"given":"Zenshiro","family":"Tamaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihide","family":"Asano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiko","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Kinugawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryozo","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2011,6,3]]},"reference":[{"issue":"1","key":"472_CR1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1346-8138.2009.00758.x","volume":"37","author":"Y Asano","year":"2010","unstructured":"Asano Y. Future treatments in systemic sclerosis. J Dermatol. 2010;37(1):54\u201370.","journal-title":"J Dermatol"},{"issue":"4","key":"472_CR2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00392-009-0752-3","volume":"98","author":"H ten Freyhaus","year":"2009","unstructured":"ten Freyhaus H, Dumitrescu D, Bovenschulte H, Erdmann E, Rosenkranz S. Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension. Clin Res Cardiol. 2009;98(4):265\u20137.","journal-title":"Clin Res Cardiol"},{"issue":"4","key":"472_CR3","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1536\/ihj.51.272","volume":"51","author":"M Hatano","year":"2010","unstructured":"Hatano M, Yao A, Shiga T, Kinugawa K, Hirata Y, Nagai R. Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension. Int Heart J. 2010;51(4):272\u20136.","journal-title":"Int Heart J"},{"key":"472_CR4","first-page":"w13050","volume":"140","author":"C Beyer","year":"2010","unstructured":"Beyer C, Distler JH, Distler O. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases? Swiss Med Wkly. 2010;140:w13050.","journal-title":"Swiss Med Wkly"},{"key":"472_CR5","unstructured":"Denton CP, Nihtyanova SI, Varga J, et al. Comparative analysis of change in modified Rodnan skin score in patients with diffuse systemic sclerosis receiving imatinib mesylate suggests similar disease course to matched patients receiving standard therapy. Arthritis Rheum. 2010;62(S10): Abstract 566."},{"key":"472_CR6","unstructured":"Spiera RF, Gordon JK, Mersten JN, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis. 2011."},{"issue":"1","key":"472_CR7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/art.22314","volume":"56","author":"JH Distler","year":"2007","unstructured":"Distler JH, Jungel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. 2007;56(1):311\u201322.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"472_CR8","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/art.20214","volume":"50","author":"PB Furspan","year":"2004","unstructured":"Furspan PB, Chatterjee S, Freedman RR. Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud\u2019s disease. Arthritis Rheum. 2004;50(5):1578\u201385.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"472_CR9","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/onc.2008.479","volume":"28","author":"S Bhattacharyya","year":"2009","unstructured":"Bhattacharyya S, Ishida W, Wu M, et al. A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate. Oncogene. 2009;28(10):1285\u201397.","journal-title":"Oncogene"},{"issue":"1","key":"472_CR10","doi-asserted-by":"crossref","first-page":"e1452","DOI":"10.1371\/journal.pone.0001452","volume":"3","author":"JN Fleming","year":"2008","unstructured":"Fleming JN, Nash RA, McLeod DO, et al. Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS One. 2008;3(1):e1452.","journal-title":"PLoS One"},{"issue":"4","key":"472_CR11","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.2353\/ajpath.2010.090593","volume":"176","author":"Y Asano","year":"2010","unstructured":"Asano Y, Stawski L, Hant F, et al. Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol. 2010;176(4):1983\u201398.","journal-title":"Am J Pathol"},{"issue":"5","key":"472_CR12","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/1529-0131(199905)42:5<930::AID-ANR11>3.0.CO;2-1","volume":"42","author":"VS Rajkumar","year":"1999","unstructured":"Rajkumar VS, Sundberg C, Abraham DJ, Rubin K, Black CM. Activation of microvascular pericytes in autoimmune Raynaud\u2019s phenomenon and systemic sclerosis. Arthritis Rheum. 1999;42(5):930\u201341.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"472_CR13","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0002-9440(10)63685-1","volume":"163","author":"M Kubo","year":"2003","unstructured":"Kubo M, Czuwara-Ladykowska J, Moussa O, et al. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol. 2003;163(2):571\u201381.","journal-title":"Am J Pathol"},{"issue":"7","key":"472_CR14","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.21948","volume":"54","author":"Y Wang","year":"2006","unstructured":"Wang Y, Fan PS, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum. 2006;54(7):2271\u20139.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"472_CR15","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1128\/MCB.01278-08","volume":"29","author":"Y Asano","year":"2009","unstructured":"Asano Y, Markiewicz M, Kubo M, Szalai G, Watson DK, Trojanowska M. Transcription factor Fli1 regulates collagen fibrillogenesis in mouse skin. Mol Cell Biol. 2009;29(2):425\u201334.","journal-title":"Mol Cell Biol"},{"issue":"7","key":"472_CR16","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1128\/MCB.01320-08","volume":"29","author":"Y Asano","year":"2009","unstructured":"Asano Y, Trojanowska M. Phosphorylation of Fli1 at threonine 312 by protein kinase C delta promotes its interaction with p300\/CREB-binding protein-associated factor and subsequent acetylation in response to transforming growth factor beta. Mol Cell Biol. 2009;29(7):1882\u201394.","journal-title":"Mol Cell Biol"},{"issue":"48","key":"472_CR17","doi-asserted-by":"crossref","first-page":"34672","DOI":"10.1074\/jbc.M703907200","volume":"282","author":"Y Asano","year":"2007","unstructured":"Asano Y, Czuwara J, Trojanowska M. Transforming growth factor-beta regulates DNA binding activity of transcription factor Fli1 by p300\/CREB-binding protein-associated factor-dependent acetylation. J Biol Chem. 2007;282(48):34672\u201383.","journal-title":"J Biol Chem"},{"issue":"35","key":"472_CR18","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041\u201351.","journal-title":"J Clin Oncol"},{"issue":"6","key":"472_CR19","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1517\/14656566.4.6.963","volume":"4","author":"BJ Druker","year":"2003","unstructured":"Druker BJ. Imatinib mesylate in the treatment of chronic myeloid leukaemia. Expert Opin Pharmacother. 2003;4(6):963\u201371.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"472_CR20","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/blood-2009-02-204156","volume":"114","author":"A Olivieri","year":"2009","unstructured":"Olivieri A, Locatelli F, Zecca M, et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood. 2009;114(3):709\u201318.","journal-title":"Blood"},{"issue":"6","key":"472_CR21","doi-asserted-by":"crossref","first-page":"R160","DOI":"10.1186\/ar2067","volume":"8","author":"A Fietta","year":"2006","unstructured":"Fietta A, Bardoni A, Salvini R, et al. Analysis of bronchoalveolar lavage fluid proteome from systemic sclerosis patients with or without functional, clinical and radiological signs of lung fibrosis. Arthritis Res Ther. 2006;8(6):R160.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"472_CR22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s100670050039","volume":"19","author":"EJ Kucharz","year":"2000","unstructured":"Kucharz EJ, Grucka-Mamczar E, Mamczar A, Brzezinska-Wcislo L. Acute-phase proteins in patients with systemic sclerosis. Clin Rheumatol. 2000;19(2):165\u20136.","journal-title":"Clin Rheumatol"},{"issue":"12","key":"472_CR23","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1164\/rccm.200702-178OC","volume":"176","author":"M Azuma","year":"2007","unstructured":"Azuma M, Nishioka Y, Aono Y, et al. Role of alpha1-acid glycoprotein in therapeutic antifibrotic effects of imatinib with macrolides in mice. Am J Respir Crit Care Med. 2007;176(12):1243\u201350.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"472_CR24","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/rheumatology\/ken104","volume":"47","author":"PP Sfikakis","year":"2008","unstructured":"Sfikakis PP, Gorgoulis VG, Katsiari CG, Evangelou K, Kostopoulos C, Black CM. Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford). 2008;47(5):735\u20137.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10165-011-0472-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T16:25:33Z","timestamp":1646843133000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10165-011-0472-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,3]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["472"],"URL":"https:\/\/doi.org\/10.1007\/s10165-011-0472-1","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,3]]}}}